VEEV
Veeva Systems
$153.16
▼ 0.1%Updated Today 7:15 PM ET
▼ Down 45.5% over the last 12 months
Market Cap
$26.54B
P/E
25.94x
Forward P/E (est.)
21.63x
ROE
13.4%
Revenue Growth
16.3%
EPS Growth
19.9%
Profit Margin
28.4%
FCF Yield
2.1%
Debt / Equity
0x
ROIC
10.0%
Interest Coverage
—
Current Ratio
4.74x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
69/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what VEEV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. VEEV trades near $153.16, below its 50-day average ($164.38) and 200-day average ($218.71). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 43 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. VEEV's is $8.94 (~5.8% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month VEEV found buyers near $153.91 (support) and sellers near $191.97 (resistance); its 52-week range is $148.05–$310.50. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.8× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Veeva Systems (VEEV) is a large-cap company in the Health Care Technology industry, part of the Health Care sector of the S&P 500, with a market value around $26.54B.
In its latest reported year it generated about $3.20B in revenue and $908.91M in net profit.
Our model rates VEEV Favorable (69/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
14.6%
Revenue moved from $1.85B in 2022 to $3.20B in 2026, a 14.6% compound annual growth rate. The most recent year grew a strong 16.3% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
75.5%
Operating Margin
28.7%
Net Margin
28.4%
ROE
13.4%
Veeva Systems keeps about 28.4% of each sales dollar as net profit, with a 75.5% gross margin and 28.7% operating margin. Return on equity is 13.4% and return on invested capital about 10.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 4.7x. That is a conservative balance sheet — a cushion in downturns.
Operating CF
$1.42B
Free Cash Flow
$1.42B
FCF Margin
44.3%
In the latest year Veeva Systems produced about $1.42B of operating cash flow and $1.42B of free cash flow after capital spending. That is a free-cash-flow yield of about 2.1% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
25.94x
P/S
8.15x
P/B
4.35x
EV / EBITDA
28.36x
VEEV trades at 25.9x trailing earnings (about 21.6x on estimated forward earnings), 8.1x sales, and 4.3x book value. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How VEEV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), VEEV ranks #8 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (25.9x P/E vs. 25.4x median) with a lower return on equity (13.4% vs. 14.9%) and faster revenue growth (16.3% vs. 7.9%).
P/E vs sector
25.9x
median 25.4x
ROE vs sector
13.4%
median 14.9%
Growth vs sector
16.3%
median 7.9%
Sector rank
#8
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$185.09 – $300.77
vs. $153.16 today · expected CAGR 4% – 14%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $4.30B | $4.99B | $5.79B | $6.71B |
| Net income | $1.04B | $1.20B | $1.40B | $1.62B | $1.88B |
| EPS | $6.39 | $7.41 | $8.60 | $9.97 | $11.57 |
| Share price (low) | $102.22 | $118.58 | $137.55 | $159.56 | $185.09 |
| Share price (high) | $166.11 | $192.69 | $223.52 | $259.28 | $300.77 |
| CAGR (low–high) | -33% / 8% | -12% / 12% | -4% / 13% | 1% / 14% | 4% / 14% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for VEEV:
- Revenue is growing 16.3% a year, a sign of real demand.
- High net margins (28.4%) point to pricing power or efficiency.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- Our model's overall read is Favorable (69/100).
The case against VEEV:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Veeva Systems is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 25.9x earnings, which our model scores Favorable (69/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.